Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous and homologous second-dose SARS-CoV-2 vaccine safety and immunogenicity study
jRCTs031210370Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of ChAdOx1 nCoV-19, tozinameran and elasomeran in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Adverse events, Electronic health assessment diary items and 4 more. Started Oct 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs031210370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210370.